Drug intelligence / Profile preview

WH009

Development stage: Preclinical
Lead developer: Beijing Wehand-Bio Pharmaceutical
Modality: Small Molecules
Administration: Parenteral, Intravenous

Overview

WH009 is a small molecule phthalazinone derivative currently under development by Beijing Wehand-Bio Pharmaceutical. It is being investigated for the treatment of stroke and dementia. Phthalazinone derivatives are a chemical class frequently explored for their neuroprotective properties, often acting through the modulation of pathways involved in ischemia-reperfusion injury and neurodegeneration. While the specific molecular target for WH009 has not been publicly disclosed by the sponsor, it represents a key asset in the company's central nervous system (CNS) pipeline.

Beyond the preview

Go deeper on WH009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WH009.

Explore the full profile